Diversity in Research
Researchers need you! Learn why diverse representation in lupus research is important for developing new lupus treatments.
There are many possible factors:
- Study researchers may not make an adequate effort to recruit and retain diverse participants.
- Health care providers may not discuss clinical trials with their patients. They may lack the time or assume that members of racial and ethnic minority and other diverse groups do not want to participate.
- Some members of diverse groups may not want to participate because they distrust the medical system, or have concerns such as the time commitment, language barriers, and transportation to trial sites.
Advances in the understanding and treatment of lupus over the past several decades have resulted in people with the disease living longer. However, there are still only a limited number of treatments available.
It is important to have diverse groups participate in lupus research to learn how different groups respond to lupus medications and treatments. Researchers need to gather data on the effectiveness, safety, and side effects of lupus treatments within the populations who are most affected. New treatments to fight lupus can only be possible if we all participate.
Clinical Trial Diversity
Food And Drug Administration
Office of Minority Health and Health Equity
Diversity in Clinical Trial Participation
Office of Patient Affairs
Did you know?
Since 2015, the FDA has been providing concise information about who participated in clinical trials that supported the FDA approval of new drugs. Learn more about Drug Trials Snapshots.